Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2025

Conditions
Myocardial Infarction
Interventions
BIOLOGICAL

WJ-MSC cells implantation

Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4\~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.

DRUG

CTSTMD PBS without WJ-MSC

For Case-control study only.

DRUG

Conventional drug therapy

All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT03533153 - Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction | Biotech Hunter | Biotech Hunter